Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

Alcon Research1,062 enrolled

Overview

The purpose of this study was to evaluate the safety and efficacy of a new ophthalmic suspension (Brinz/Brim) in lowering intraocular pressure (IOP) relative to its individual active components in subjects with open-angle glaucoma and/or ocular hypertension.

This study consisted of 7 visits conducted during 2 sequential phases: the screening/eligibility phase, which included a screening visit and 2 eligibility visits, and the treatment phase, which included 4 on-therapy visits conducted at Week 2, Week 6, Month 3, and Month 6. A washout period based on previous ocular medication preceded Eligibility Visit 1. Subjects who met all inclusion/exclusion criteria at both eligibility visits were randomized to 1 of 3 study drug groups. The study was designed to evaluate the efficacy and safety of Brinzolamide/Brimonidine over a 3-month period, with an additional 3 months of study drug exposure intended to provide further safety data.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

1,062

Conditions

Open-Angle Glaucoma Ocular Hypertension

Interventions

Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspensionDRUG

Brinzolamide ophthalmic suspension, 1%DRUG

Brimonidine tartrate ophthalmic solution, 0.2%DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Sign Informed Consent document. * Diagnosis of open-angle glaucoma or ocular hypertension, with mean intraocular pressure within protocol-specified range at eligibility visit/s. * Other protocol-specified inclusion criteria may apply. Exclusion Criteria: * Females of childbearing potential if pregnant, lactating, or not using highly effective birth control measures. * Any form of glaucoma other than open-angle glaucoma. * Severe central vision loss in either eye. * Chronic, recurrent, or severe inflammatory eye disease. * Ocular trauma within the preceding 6 months. * Ocular infection or ocular inflammation within the preceding 3 months. * Clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment. * Best-corrected visual acuity score worse than 55 letters using the Early Treatment Diabetic Retinopathy Study chart. * Other ocular pathology (including severe dry eye) that may, in the opinion of the Investigator, preclude the administration of study product. * Ocular surgery within the preceding 6 months. * Ocular laser surgery within the preceding 3 months. * Any abnormality preventing reliable applanation tonometry. * Any other conditions, including severe illness, which could make the subject, in the opinion of the Investigator, unsuitable for the study. * Other protocol-specified exclusion criteria may apply.

Outcomes

Primary Outcomes

Mean Intraocular Pressure (IOP) at Each Assessment Timepoint (8 AM, +2 h, +7 h, and +9 h) at Month 3

The study drug was instilled at 8 AM and 3 PM (approximately 15 minutes after conducting the IOP measurements). Intraocular pressure was measured by Goldmann applanation tonometry. One eye from each patient was chosen as the study eye and only data for the study eye were used for the efficacy analysis. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).

Time frame: Month 3

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.